Ormetoprim (OMP) Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine, a diaminopyrimidine active pharmaceutical ingredient supplied as a white to off-white crystalline powder. The molecular formula C₁₄H₁₈N₄O₂ corresponds to a relative molecular mass of 274.32 g/mol; the CAS Registry Number is 6981-18-2. The product is offered under model designations OMP-VET-100 for tablet, capsule, and powder processing; OMP-VET-210 for parenteral use with reduced bacterial endotoxin; and OMP-VET-305 for premix and granulation operations requiring controlled particle size. OMP is not a sulfonamide. It is combined with sulfadimethoxine at a ratio of 1:5 in potentiated sulfonamide dosage forms intended for dogs, chickens, and turkeys. Because no harmonized Ph. Eur. or USP monograph for OMP is available, release testing is typically performed against a validated in-house specification derived from VICH GL2 requirements and current veterinary GMP expectations.

How Should a Release Specification Be Structured When No Ph. Eur. Monograph Exists?

The absence of a harmonized pharmacopoeial monograph shifts the control burden to the API manufacturer and the veterinary finished-product holder. A release specification for OMP should cover identity, assay, related substances, residual solvents, water content, residue on ignition, elemental impurities, particle size, and — for parenteral grade — bacterial endotoxin and sterility. Table 1 lists typical certified limits for OMP-VET-210; values are representative of non-compendial veterinary API documentation and should be verified against the manufacturer’s current certificate of analysis.

Assay and related-substance methods for OMP typically employ reversed-phase high-performance liquid chromatography with a C18 column, a phosphate or acetate mobile phase adjusted to an acidic pH, and ultraviolet detection near 230 nm or 270 nm. The method should be validated for specificity, linearity, accuracy, precision, and solution stability according to VICH GL2. Because OMP is a weakly basic diaminopyrimidine, sample preparation for assay normally requires dissolution in dilute hydrochloric acid or an acidified aqueous-organic diluent; neutral aqueous diluents may produce incomplete dissolution and low assay results.

Solid-state characterization is part of the API control strategy. The crystalline form should be confirmed by X-ray powder diffraction, and the melting behavior should be recorded by differential scanning calorimetry. Published OMP-specific polymorph data are limited; therefore, a change in crystalline form or thermal behavior should be investigated before batch release. The bulk material is stored in tightly closed containers at controlled room temperature. If a bulk container is opened under relative humidity above 60%, drying before use is recommended because residual surface moisture can affect powder flow and punch filming during compression.

Tablet and capsule development with OMP usually requires particle size reduction or geometric dilution to achieve content uniformity in low-dose units. For tablet formulations produced by direct compression, OMP is blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate. Blend uniformity samples should be collected at 10 locations using a sampling thief; acceptance limits of 90.0–110.0% label claim with relative standard deviation ≤ 5.0% are common for veterinary powders, though published OMP-specific blend validation data are limited. Tablet hardness is typically targeted at 5–8 kPa for chewable tablets and 8–12 kPa for swallow tablets; these values require confirmation with the finished formulation and the intended animal species. Dissolution testing, if required, can be performed using USP Apparatus 2 at 75 rpm in 900 mL of 0.1 N hydrochloric acid; published OMP-specific dissolution acceptance criteria are limited.

Capsule filling of OMP-containing blends demands controlled particle size and adequate flow. Direct filling of capsules below 10 mg OMP per unit requires geometric dilution with lactose monohydrate or microcrystalline cellulose to prevent segregation. Granules intended for oral reconstitution should be evaluated for wetting time and dispersibility in purified water at 20°C. For oral powders, the API may be dry-blended with dextrose, sucrose, or other compatible carriers; the final powder should pass through a 500 µm sieve to break loose agglomerates before packaging.

Structural and Pharmacokinetic Differences Between OMP and Trimethoprim

OMP differs from trimethoprim by the substitution pattern on the benzyl ring: OMP bears a 4,5-dimethoxy-2-methylbenzyl group, whereas trimethoprim carries a 3,4,5-trimethoxybenzyl group. This structural change modifies the inhibitor’s affinity for bacterial dihydrofolate reductase and its distribution in target species. In veterinary medicine, OMP is used almost exclusively with sulfadimethoxine in a 1:5 ratio, while trimethoprim is more commonly paired with sulfadiazine or sulfamethoxazole at 1:5 in other species. Table 2 summarizes formulation-relevant differences.

Published comparative pharmacokinetic data for OMP and trimethoprim in all veterinary species are limited. In dogs, the sulfadimethoxine/OMP combination is administered once daily; this dosing interval is primarily driven by sulfadimethoxine elimination, not by an independently long OMP half-life. The practical difference is that OMP-containing veterinary formulations should not be interchanged with trimethoprim-containing products without a species-specific bioequivalence evaluation. Other veterinary diaminopyrimidines, such as baquiloprim and aditoprim, have different species approvals and elimination profiles; OMP is specifically positioned in sulfadimethoxine combinations for dogs and poultry.

For oral solutions and drinking-water formulations, the pH-dependent solubility of OMP requires acidification before complete dissolution. A stock solution can be prepared by dispersing OMP in purified water, adding hydrochloric acid to pH 2.5–3.5, and then diluting to the intended use concentration. Phosphate-buffered media at pH 7.4 should be avoided because precipitation of the free base may occur. Published solubility data for OMP in cosolvent systems such as propylene glycol-water or ethanol-water are limited; therefore, formulation development should include a phase-solubility study and visual precipitation screening at 2–8°C and 25°C. The final oral solution should be protected from light and stored in high-density polyethylene or amber glass containers.

Applying Heat and Shear During Premix Production

Premix and granule operations involve dry blending with carriers such as ground corn, soybean meal, or calcium carbonate at active premix inclusion rates from 0.2% to 5.0% w/w. Ribbon mixers or double-cone blenders with fill volumes of 50–70% are used; blender speed and mixing time must be validated for each batch size. If the medicated feed is subjected to pelleting or extrusion, the thermal stability of OMP must be established under the actual conditioner temperature and residence time. Published data for OMP degradation in feed matrices under pellet mill conditions are limited; a forced degradation study at 80°C for 24 h is a reasonable screening condition, but it does not replace a scale-down production trial. Carryover control in feed mills is required because OMP is a dihydrofolate reductase inhibitor; equipment cleaning should be validated with a limit of detection appropriate for the target species.

Granulation of OMP in high-shear mixers should be monitored for granule size distribution and moisture content after drying. A final granule moisture content of 1.0–2.0% is often suitable for compression; overwetting can produce hard granules that resist disintegration, while overdrying can increase fines and tablet capping. If fluidized-bed drying is used, inlet air temperature should be controlled to avoid degradation of the API. Published degradation kinetics for OMP under fluidized-bed conditions are limited; therefore, a short-duration drying validation is necessary before scale-up.

When OMP Is Compounded into Injectable Solutions: pH, Solubility, and Sterility Constraints

Injectable dosage forms require OMP-VET-210 or an equivalent low-endotoxin grade. Terminal sterilization by moist heat at 121°C for 15 min is preferred, but the chemical stability of OMP under these conditions must be confirmed. Aqueous formulations are usually developed at acidic pH, often pH 3.0–4.0, using hydrochloric acid or citric acid as pH adjusters. The injection vehicle should be inspected for turbidity after cooling to 2–8°C; precipitation at low temperature indicates that the OMP concentration exceeds the equilibrium solubility of the chosen vehicle. Sterile filtration through 0.22 µm polyethersulfone or polyvinylidene fluoride membranes is possible only if the API is fully dissolved and filter compatibility has been demonstrated. Incompatibility with alkaline buffers and with strong oxidizing agents should be assumed until forced degradation data are available.

For injectable products, particulate matter should be evaluated according to USP <788>, and bacterial endotoxin limits should be established based on the maximum dose and animal species. The API is intended for veterinary use only and is not for human medicine. If the parenteral formulation includes propylene glycol or ethanol as a cosolvent, the final product must be assessed for injection-site tolerance in the target species. Published OMP-specific data for organic cosolvent systems are limited, so a conservative vehicle selection and a short-term accelerated stability study are recommended before pivotal batch manufacture.